Chaoju Eye Care Holdings Ltd. has announced that its subsidiary, Chaoju Medical Technology, has subscribed to wealth management products offered by BOC, totaling RMB240 million. This transaction, funded by surplus cash, is part of a series of similar subscriptions and is classified as a discloseable transaction under the Hong Kong Stock Exchange's Listing Rules. The subscription is expected to impact the company's financial strategy by utilizing surplus cash for investment purposes, potentially influencing its financial positioning and offering insights into its cash management practices.